Mayo Clinic said this about GERN's drug below on page 10. "g. Some patients participating in the clinical trial taking imetelstat obtained dramatic responses, and we have seen some complete responses (tantamount to a cure), which is almost unheard of in this disease." "Although patients may experience relief in response to other treatments, their bone marrow does not usually return to normal. But in the case of this new therapy, some of the patients participating in the trial developed normal bone marrow." http://www.mayo.edu/pmts/mc7300-mc7399/mc7323.pdf
Volume for June 23, 2017 was 1,737,000
This started as a low volume day but at the end of the day more than 300,000 shares traded with no significant pps. After hours trading is over 168,000.
Someone is expecting something to happen and it looks like before month end.
Take a couple week holiday and I see I've missed nothing. Same old tired pumps as the last 5+ years. Carry on.
GERN shareholders soon will be tired of winning.
Amazing to see the diversity. The amount of creativity that some here demonstrate, in formulating complex theories about how and why this stock behaves as it does, is impressive to read and watch. No judgement call here. Just fascinating to watch how the human brain, for whatever motivation, can create such complex scenarios. We have Al Gore to thank for inventing the internet.
134,000 shares traded in first 40 minutes of AHT. This isn't the 3rd Friday of the month. Anybody got any idea why?
What the CEO said about Imetelstat was
"it's done things that no other drug has been able to do" While the, now removed, Mayo Clinic article quoted Dr. Tefferi as saying
Some patients in our clinical trial taking imetelstat obtained dramatic responses and there have been some complete responses which is almost unheard of for drug therapy in this disease. In his presentation at ASH, Dr. Tefferi did spell out
Naked Short Report, Nasdaq and NYSE Naked Short Positions, Short Selling Interest
Naked Short Report - track short selling interest on NASDAQ and NYSE STOCKS, check daily short interest, naked short data and short squeeze stock perfomance
Part I I'm not sure about never seeing $3 again as some have suggested. However, there are some compelling reasons why there is likely to be a price spike, sooner, rather than later. If you follow the FDA.gov site for GERN, you would know that the original filing was back in 2012 and the expected duration of the trials is until Jan 2019. (1.5 years from now) That could certainly be extended. At the same time, due to no other effective treatments for the diseases currently being targeted, there could also be acceleration to Market, the FDA has more than one path for that. Why there could be a spike in the near future has to with the fact that a great deal now hinges on Phase III's. To paraphrase, the CEO, Scarlett of GERN said that Janssen's decision to move forward with the IMerge Phase III (Which would enroll by the end of this year was expected by the end of THIS quarter. This Quarter ends in 1 week. Since it appears the internal reviews have been completed the natural question should be: Why is Janssen taking it's time announcing the decision to move forward with the Phase III? My answer is... 65 Million reasons. After that decision, Janssen is to send over 65 Million dollars to GERN as a milestone payment. So that decision is not just about the hypothetical future value of GERN, it's about some serious revenues this year. Janssen isn't likely to make that decision, and send over 65 Million if it doesn't look good. Its in fact a very serious commitment from a very serious player. To me, that would be favorable for the stock price. How high it would spike and how much it would retrace are certainly good questions. For many years GERN has had short term spikes, then sinks back into the mud. Traders may be expecting that buy the rumor, sell the news pattern to continue. In my view what would change that pattern is an increasing interest (and stake) from longer term institutional holders. In my research it appears there have been such institutions that have come and gone. This year, it seems like there are some who are increasing their stake. What would happen if Janssen does announce the decision to continue investigation and begin enrolling for the IMerge Phase III by the end of this year?
Once again, Jackdaw proclaims that tiny "stock players" are overpowering poor little Berkshire Hathaway, Fidelity, BlackRock, etc. etc. etc. Not to mention JNJ itself... the billion it would take to buy 51% of GERN isn't even material to them.
How do they do it, Jack? Magic wands? Alien technology?
The big funds have trillions of dollars. JNJ just spent some, but they still have over 30 Billion, IIRC. Yet somehow they are all overpowered by Jackdaw's little "short playah". How exactly does that work, jack? National Enquiring minds want to know!
CIA Captured Putin's Instructions to Help Elect Trump - Political Wire
“Early last August, an envelope with extraordinary handling restrictions arrived at the White House. Sent by courier from the CIA, it carried ‘eyes only’ instructions that its contents be shown to just four people: President Barack Obama and three se
We shoot past $3.00 tomorrow and never look back!!!!!!!!!!!!!!
FDA Approves Imbruvica for Frontline Treatment of CLLPublished March 04, 2016The FDA has approved Imbruvica (ibrutinib) for the frontline treatment of chronic lymphocytic leukemia (CLL), based on data from the RESONATE-2 trial.1,2Check out this CT for Imbruvica completed January 23, 2017. This looks very similar to what #$%$ posted on the last update to the Mayo Clinic Trial. Notice they eliminate the authority similar to what #$%$ posted.https://clinicaltrials.gov/archive/NCT02169180/2017_01_23/changes
ClinicalTrials.gov Identifier: NCT01731951 First received: November 18, 2012 Last updated: June 16, 2017 Last verified: June 2017
Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis - Full Text View - ClinicalTrials.gov
Resist taking profits today, you may regret your re-entry point otherwise.
YTD 42.03% dang nice return unless your BLACK
Does anybody here know the current status of Imetelstat with regard to multiple myeloma? Is there any ongoing clinical trial employing Imetelstat in multiple myeloma, or has that been shelved? I have been searching the Internet. There's something about a Phase II trial a few years ago for which results were never forthcoming????? Does anybody on this board have a clue about this? Imetelstat has been around for years now. It was said to destroy cancer stem cells and thus prevent metastasis. If that's the case, why isn't it already available? Is it being suppressed by big pharma which prefers to continue to market their chemo across the world helping cancer patients to survive an added six months on average Is this their answer to the problem of overpopulation? I have a friend with multiple myeloma. What do we have to do to get Imetestat for her? Anybody?
BM did you really have to post this following POS post from you here?
Blackmarango3 hours ago A comment that I made on the SA board which should concern ALL GERN investors!
1. In a previous SEC Annual Report, chippy used the words "Confidential" or "Confidentiality" 234 times. Why so much Secrecy?
Damn BM, you're still pushing that garbage about the 234 "confidential" mentions? That's 3 to 5 year old material from you...Next thing you know, you'll be pushing the old garbage of veil of silence BS..Don't you ever live in the now?
What made you think that this board would be interested in anything you wrote on SA? SA probably deleted your post because you're an irrelevant poster..You've become a tired old foolish Skunk..Retire your BS self.
Jack, you're still posting nothing, and you're doing it in all caps. Trading isn't "easy money", you certainly can't do it. Instead of reinforcing your age-related schizphrenia, try to break out of it. Instead of evading the question, just answer it in your own mind:
How are your tiny "stock players" overpowering poor little Berkshire Hathaway, Fidelity, BlackRock, etc. etc. etc. Not to mention JNJ itself... the billion it would take to buy 51% of GERN isn't even material to them.
How do they do it, Jack? Answer that question, and the mysteries that plague you will be solved.
...or you can just admit that only 30% of Phase 2 drugs even make it to Phase 3, and fewer yet make it to approval. There's no mystery why a 27-year-old shell company with one Phase 2 drug is heavily shorted.